CAPE COD
This trial evaluated the effect of hydroxycortisone on survival or respiratory support among patients with critical COVID-19
Primary objective: To determine the effect of hydrocortisone on treatment failure on day 21 in critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute respiratory failure
Type of study: Interventional, RCT, Phase 3
Treatment tested: Hydroxycortisone
Countries: France
Number of sites: N/A
Sample size: 290
Study participants: Adults, COVID-19 confirmed by PCR or suspected (suggestive chest computed tomography scan result in the absence of any other cause of pneumonia) , admitted in ICU
Study status: Completed
Study documents
Principal investigator
- Pierre-François DEQUIN, MD PhD, CHRU Tours , France pierre-françois.dequin@univ-tours.fr
More information
- Study ID: NCT02517489
- Trial registry
- Publication: JAMA, September 2020
Last updated: September 2020
Disclaimer
Note that study-related documents posted on the COVID-19 Clinical Research Coalition (COVID-19 CRC) website have been shared by coalition members for information. Some may have been approved by Ethics Review Boards and others may still be in draft form. Documents posted here may have been further amended before being used in the conduct of the respective trials they were designed for. It is recommended that users review these documents carefully and, if they plan to use them, adapt them appropriately for their intended use. The COVID-19 CRC and its members cannot accept any liability for any claim, loss or damages as a result of any reliance placed on, or use of, these documents.